乳腺癌患者HER-2胞外结构域的临床价值

doi:10.3969/j.issn.1673-8640.2017.010.008

摘要/Abstract

摘要：

目的探讨乳腺癌患者血清人类表皮生长因子受体2（HER-2）胞外结构域（ECD）的临床价值。方法选取乳腺癌患者93例、良性乳腺病患者40例及健康女性（正常对照组）55名,采用化学发光法定量检测所有对象血清HER-2 ECD水平,并分析乳腺癌患者血清 HER-2 ECD水平与癌组织HER-2表达状态的一致性、血清HER-2 ECD与乳腺癌临床病理特征的关系及其对乳腺癌的诊疗效能。结果乳腺癌组血清HER-2 ECD水平[16.00（12.30,20.10）ng/mL]明显高于良性乳腺病组[6.05（4.85,7.95）ng/mL,P<0.05]和正常对照组[5.30（4.00,6.80）ng/mL,P<0.05]。乳腺癌患者癌组织HER-2表达阳性者的血清HER-2 ECD阳性率为73.08%,血清HER-2 ECD与癌组织HER-2表达的一致性较好。不同组织学分级、有无淋巴结转移及不同临床分期的乳腺癌患者血清HER-2 ECD水平差异有统计学意义（P<0.05）。结论乳腺癌患者血清HER-2 ECD与乳腺癌的临床特征关系密切,有望成为早期诊断乳腺癌、监测疗效、判断预后的重要指标之一。

关键词: 人类表皮生长因子受体2, 乳腺癌, 化学发光法

Abstract:

Objective To investigate the role of serum human epidermal growth factor receptor 2（HER-2）extracellular domain（ECD）in breast cancer patients. Methods A total of 93 breast cancer patients,40 benign breast disease patients and 55 healthy females were enrolled,and serum HER-2 ECD levels were determined by chemiluminescence. The consistency between serum HER-2 ECD level and the expression of tissue HER-2,the relation between serum HER-2 ECD and clinical pathological characteristics,and the efficacy in diagnosing breast cancer were analyzed. Results The level of serum HER-2 ECD in breast cancer group [16.00（12.30,20.10）ng/mL] was higher than those in benign breast disease group [6.05（4.85,7.95）ng/mL,P<0.05] and healthy control group [5.30（4.00,6.80）ng/mL,P<0.05]. The positive rate of serum HER-2 ECD in breast cancer patients with tissue HER-2 expression positive was 73.08%,and the consistency between serum HER-2 ECD and tissue HER-2 expression was good. The difference of serum HER-2 ECD levels with different histological grades,lymph node metastasis or not and different clinical stages had statistical significance（P<0.05）. Conclusions Serum HER-2 ECD is related to the clinical characteristics of breast cancer. So,it is expected to become a valuable laboratory parameter in diagnosing breast cancer in early stage,monitoring treatment efficacy and judging the prognosis of breast cancer patients.

Key words: Human epidermal growth factor receptor 2, Breast cancer, Chemiluminescence

中图分类号:

R446.61

郭奕阳, 邓艳丽, 郭秀娟, 张金艳. 乳腺癌患者HER-2胞外结构域的临床价值[J]. 检验医学, 2017, 32(10): 871-874.

GUO Yiyang, DENG Yanli, GUO Xiujuan, ZHANG Jinyan. Serum HER-2 extracellular domain for breast cancer patients[J]. Laboratory Medicine, 2017, 32(10): 871-874.

图/表 3

参考文献 19

[1]	STRASSER-WEIPPL K,HORICK N,SMITH I E,et al.Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy[J]. Eur J Cancer,2016,56:85-92.
[2]	KIM C,LEE J,LEE W,et al.Changes in intrinsic subtype of breast cancer during tumor progression in the same patient[J]. Int J Clin Exp Pathol,2015,8(11):15184-15190.
[3]	MYERS M B.Targeted therapies with companion diagnostics in the management of breast cancer:current perspectives[J]. Pharmgenomics Pers Med,2016,9:7-16.
[4]	KIJANKA M M,VAN BRUSSEL A S,VAN DER WALL E,et al. Optical imaging of pre-invasive breast cancer with a combination of VHHs targeting CAIX and HER2 increases contrast and facilitates tumour characterization[J]. EJNMMI Res,2016,6(1):14.
[5]	《乳腺癌HER2检测指南(2014版)》编写组. 乳腺癌HER2检测指南(2014版)[J]. 中华病理学杂志,2014,43(4):262-267.
[6]	YAMAMURA J,KAMIGAKI S,HAMAKAWA T,et al.Efficacy and safety of pertuzumab for HER2-positive metastatic breast cancer[J]. Gan To Kagaku Ryoho,2015,42(6):713-717.
[7]	廖天,陆云飞. 乳腺癌患者手术和化疗前后血清HER2 ECD水平的变化[J]. 肿瘤防治研究,2010,37(4):435-437.
[8]	周爱清,陈志军,孙正魁,等. 乳腺癌患者血清HER-2/neu浓度与组织HER-2表达水平的相关性[J]. 实用癌症杂志,2015,31(4):479-481.
[9]	QUARANTA M,DANIELE A,COVIELLO M,et al.C-erbB-2 protein level in tissue and sera of breast cancer patients:a possibly useful clinical correlation[J]. Tumori, 2006, 92(4):311-317.
[10]	NAKATSUKASA K,KOYAMA H,OOUCHI Y,et al.Docetaxel,cyclophosphamide,and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer[J]. Breast Cancer,2017,24(1):92-97.
[11]	INOUE K,FRY E A.Aberrant splicing of estrogen receptor,HER2,and CD44 genes in breast cancer[J]. Genet Epigenet,2015,7:19-32.
[12]	原庆会,何伟,王安群,等. 乳腺癌组织中ER、PR、HER-2、BRCA-1的表达情况及与远期预后的关系[J]. 医学综述,2015,22(4):722-723.
[13]	HWANG H C,GOWN A M.Evaluation of human epidermal growth factor receptor 2(HER2) gene status in human breast cancer formalin-fixed paraffin-embedded(FFPE) tissue specimens by fluorescence in situ hybridization(FISH)[J]. Methods Mol Biol,2016,1406:61-70.
[14]	GUO T,REN Y,WANG B,et al.Promoter methylation of BRCA1 is associated with estrogen, progesterone and human epidermal growth factor receptor-negative tumors and the prognosis of breast cancer:a meta-analysis[J]. Mol Clin Oncol,2015,3(6):1353-1360.
[15]	董良,李海金,赵建刚,等. 乳腺癌分子分型与区域淋巴结转移的关系[J]. 浙江临床医学,2014,16(8):1201-1203.
[16]	BRADY S W,ZHANG J,TSAI M H,et al.PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition[J]. Cancer Biol Ther,2015,16(3):402-411.
[17]	BRUFSKY A M.Delaying chemotherapy in the treatment of hormone receptor-positive,human epidermal growth factor receptor 2-negative advanced breast cancer[J]. Clin Med Insights Oncol,2015,9:137-147.
[18]	KIM H,CHO J,KWON S Y,et al.Biologic subtype is a more important prognostic factor than nodal involvement in patients with stages Ⅰ and Ⅱ breast carcinoma[J]. Ann Surg Treat Res,2016,90(1):1-9.
[19]	PALLUD C,GUINEBRETIERE J M,GUEPRATTE S,et al.Tissue expression and serum levels of the oncoprotein HER-2/neu in 157primary breast tumours[J]. Anticancer Res,2005,25(2B):1433-1440.